Lauren M Hurwitz1,2, Jennifer Cullen1,2,3, Daniel J Kim4, Sally Elsamanoudi1,2,4, Jane Hudak1,2,4, Maryellen Colston1,2,4, Judith Travis1,2,4, Huai-Ching Kuo1,2, Kevin R Rice1,4, Christopher R Porter1,5, Inger L Rosner1,3,4. 1. Center for Prostate Disease Research, Department of Defense, Rockville, Maryland. 2. Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland. 3. Uniformed Services University of the Health Sciences, Department of Surgery; Bethesda, Maryland. 4. Department of Urology, Walter Reed National Military Medical Center, Bethesda, Maryland. 5. Virginia Mason Medical Center, Department of Urology; Seattle, Washington.
Abstract
BACKGROUND: Prostate cancer patients diagnosed with low- and intermediate-risk disease have several treatment options. Decisional regret after treatment is a concern, especially when poor oncologic outcomes or declines in health-related quality of life (HRQoL) occur. This study assessed determinants of longitudinal decisional regret in prostate cancer patients attending a multidisciplinary clinic and treated with radical prostatectomy (RP), external beam radiation therapy (EBRT), brachytherapy (BT), or active surveillance (AS). METHODS: Patients newly diagnosed with prostate cancer at the Walter Reed National Military Medical Center who attended a multidisciplinary clinic were enrolled into a prospective study from 2006 to 2014. The Decision Regret Scale was administered at 6, 12, 24, and 36 months posttreatment. HRQoL was also assessed at regular intervals using the Expanded Prostate Cancer Index Composite and 36-item RAND Medical Outcomes Study Short Form questionnaires. Adjusted probabilities of reporting regret were estimated via multivariable logistic regression fitted with generalized estimating equations. RESULTS: A total of 652 patients met the inclusion criteria (395 RP, 141 EBRT, 41 BT, 75 AS). Decisional regret was consistently low after all of these treatments. In multivariable models, only African American race (odds ratio, 1.67; 95% confidence interval, 1.12-2.47) was associated with greater regret across time. Age and control preference were marginally associated with regret. Regret scores were similar between RP patients who did and did not experience biochemical recurrence. Declines in HRQoL were weakly correlated with greater decisional regret. CONCLUSION: In the context of a multidisciplinary clinic, decisional regret did not differ significantly between treatment groups but was greater in African Americans and those reporting poorer HRQoL. Cancer 2017;123:4252-4258.
BACKGROUND:Prostate cancerpatients diagnosed with low- and intermediate-risk disease have several treatment options. Decisional regret after treatment is a concern, especially when poor oncologic outcomes or declines in health-related quality of life (HRQoL) occur. This study assessed determinants of longitudinal decisional regret in prostate cancerpatients attending a multidisciplinary clinic and treated with radical prostatectomy (RP), external beam radiation therapy (EBRT), brachytherapy (BT), or active surveillance (AS). METHODS:Patients newly diagnosed with prostate cancer at the Walter Reed National Military Medical Center who attended a multidisciplinary clinic were enrolled into a prospective study from 2006 to 2014. The Decision Regret Scale was administered at 6, 12, 24, and 36 months posttreatment. HRQoL was also assessed at regular intervals using the Expanded Prostate Cancer Index Composite and 36-item RAND Medical Outcomes Study Short Form questionnaires. Adjusted probabilities of reporting regret were estimated via multivariable logistic regression fitted with generalized estimating equations. RESULTS: A total of 652 patients met the inclusion criteria (395 RP, 141 EBRT, 41 BT, 75 AS). Decisional regret was consistently low after all of these treatments. In multivariable models, only African American race (odds ratio, 1.67; 95% confidence interval, 1.12-2.47) was associated with greater regret across time. Age and control preference were marginally associated with regret. Regret scores were similar between RP patients who did and did not experience biochemical recurrence. Declines in HRQoL were weakly correlated with greater decisional regret. CONCLUSION: In the context of a multidisciplinary clinic, decisional regret did not differ significantly between treatment groups but was greater in African Americans and those reporting poorer HRQoL. Cancer 2017;123:4252-4258.
Authors: Connor M Forbes; Kemberlee Bonnet; Tracy Bryant; David G Schlundt; Kerri L Cavanaugh; Ryan S Hsi Journal: Urolithiasis Date: 2022-06-14 Impact factor: 2.861
Authors: Nnenaya Q Agochukwu; Daniela Wittmann; Nicholas R Boileau; Rodney L Dunn; James Montie; Tae Kim; David C Miller; James Peabody; Noelle E Carlozzi Journal: J Clin Oncol Date: 2020-01-02 Impact factor: 50.717
Authors: Donna L Berry; Fangxin Hong; Traci M Blonquist; Barbara Halpenny; Niya Xiong; Christopher P Filson; Viraj A Master; Martin G Sanda; Peter Chang; Gary W Chien; Randy A Jones; Tracey L Krupski; Seth Wolpin; Leslie Wilson; Julia H Hayes; Quoc-Dien Trinh; Mitchell Sokoloff Journal: Urol Oncol Date: 2021-01-19 Impact factor: 2.954
Authors: Luka Flegar; Martin Baunacke; Bjoern Thorben Buerk; Rick Proschmann; Aristeidis Zacharis; Stefan Propping; Johannes Huber; Christian Thomas; Angelika Borkowetz Journal: Urol Int Date: 2021-11-23 Impact factor: 1.934
Authors: Nina C A Vermeer; Maxime J M van der Valk; Heleen S Snijders; Hans F A Vasen; Arthur Gerritsen van der Hoop; Onno R Guicherit; Gerrit-Jan Liefers; Cornelis J H van de Velde; Anne M Stiggelbout; Koen C M J Peeters Journal: Psychooncology Date: 2020-04-14 Impact factor: 3.894